Immunocore Holdings plc (IMCR): Shareholders' Equity
$381.03M
As of 2025-12-31
$419.80M
As of 2026-06-30
+4.0%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $381.03M | +5.6% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $360.72M | -2.2% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $368.84M | +8.8% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $338.90M | +45.0% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $233.71M | n/a | 2024-02-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $381.03M | +5.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $1.22B | +28.9% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $472.96M | +0.1% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $343.43M | +53.0% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $477.32M | +36.8% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $218.79M | +7.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $354.64M | +21.5% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $698.58M | -1.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $87.80M | +49.0% |
Compare IMCR, KRYS, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗